Comparative clinical pharmacology and therapeutic use of bisphosphonates in metabolic bone diseases

Drugs

Volumn 51, Issue 4, 1996, Pages 537-551

  Rosen, Clifford J ^a   Kessenich, Cathy R ^b  

^a ST JOSEPH HOSPITAL   (United States)

^b HUSSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; CORTICOSTEROID; ETIDRONIC ACID; PAMIDRONIC ACID; TILUDRONIC ACID;

ABDOMINAL PAIN; ACUTE KIDNEY FAILURE; ADULT; AGED; BONE ATROPHY; BONE DEMINERALIZATION; BONE DISEASE; BONE TURNOVER; CONSTIPATION; DIARRHEA; DIGESTIVE SYSTEM ULCER; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG ERUPTION; DRUG MECHANISM; DRUG METABOLISM; DRUG STRUCTURE; DYSPEPSIA; FEVER; GASTROINTESTINAL SYMPTOM; HEARING LOSS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA; METABOLIC BONE DISEASE; NAUSEA; ORAL DRUG ADMINISTRATION; OSTEOMALACIA; OSTEOPOROSIS; PAGET BONE DISEASE; POSTMENOPAUSE OSTEOPOROSIS; REVIEW;

EID: 0029872576     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199651040-00003     Document Type: Review

References (80)

1. Rosen CJ. The role of bisphosphonates and fluorides in the prevention and treatment of osteoporosis. Top Geriatr Rehabil 1995; 10: 19-34
2. Fleisch H, Russell RG, Francis MD. Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo. Science 1969; 165: 1262-4
3. Muhlbauer RC, Bauss F, Schenk R, et al. BM 2109955, a potent new bisphosphonate to inhibit bone resorption. J Bone Miner Res 1991; 6: 1003-11
4. Fleisch H. Bisphosphonates: pharmacology and use in the treatment of tumour-induced hypercalcemia and metastic bone disease. Drugs 1991; 42: 919-44
5. Sato M, Gasser W, Endo N, et al. Bisphosphonate action: alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest 1991; 88: 2095-105
6. Fleisch H. Bisphosphonates: a new class of drugs in diseases of bone and calcium metabolism. In: Baker PF, editor. Handbook of experimental pharmacology. Vol. 83. Berlin: Springer, 1988: 441-66
7. Fleisch H. Bisphosphonates: pharmacology. Semin Arthritis Rheum 1994; 23: 261-2
8. Jilka RL, Hangoc G, Girasole G, et al. Increased osteoclast development after estrogen loss: mediation by IL-6. Science 1992; 257: 88-91
9. Sahni M, Guenther HL, Fleisch H, et al. Bisphosphonates act on rat bone resorption through the mediation of osteoblasts. J Clin Invest 1993; 93: 2004-11
10. Monkkonen J, Pennanen N, Lapinjoki S, et al. Clodronate inhibits LPS stimulated IL-6 and TNF production by RAW 264 cells. Life Sci 1994; 54: 229-34
11. Passeri G, Girasole G, Utletti V, et al. Bisphosphonates inhibit IL-6 production by human osteoblastic cells. J Bone Res 1994; 9: S1
12. Fleisch H. Bisphosphonates in osteoporosis: an introduction. Osteoporos Int 1993; 3: S3-5
13. Dunt C-J, Fitton A, Sorkin EM. Etidronic acid: a review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. Drugs Aging 1994; 6: 446-74
14. Lin JH, Chen I-W, Duggan DE. Effects of dose, sex, and age on the disposition of alendronate, a potent anti-osteolytic bisphosphonate. Drug Metab Disp; 1993; 20: 473-8
15. Lin JH, Chen IW, Florencia A, et al. Renal handling of alendronate in rats: an uncharacterized renal transport system. Drug Metab Disp 1992; 20: 608-13
16. Monkkonen J, Koponene H-M, Ylitalo P. Comparison of the distribution of three bisphosphonates in mice. Pharmacol Toxicol 1989; 65: 294-8
17. Geddes AS, Bevan JA, Kasting GB. Retention of bisphosphonate in bone: quantitation of etidronate in iliac crest biopsy samples from patients on intermittent therapy for postmenopausal osteoporosis. J Bone Miner Res 1992; 7: S1-328
18. Kasting GB, Francis MD. Retention of etidronate in human, dog and rat. J Bone Miner Res 1992; 7: 513-22
19. Evans RA, Somers NM, Dunstan CR, et al. The effect of low dose cyclical etidronate and calcium on bone mass in early postmenopausal women. Osteoporos Int 1993; 3: 71-5
20. Jowsey J, Riggs BL, Kelly PJ, et al. The treatment of osteoporosis with disodiumethan 1-hyroxy-1,1-diphosphonate. J Lab Clin Med 1971; 78: 574-84
21. Heaney RP, Saville PD. Etidronate disodium in postmenopausal osteoporosis. Clin Pharmacol Ther 1976; 20: 593-604
22. Licata AA. From bathtub ring to osteoporosis. Cleve Clin J Med 1964; 60: 284-9
23. Boyce BE, Fogelman I, Ralston S. Focal osteomalacia due to low-dose diphosphonate therapy in Paget's Disease. Lancet 1984; 1: 821-4
24. Storm T, Steiniche T, Thamsborg G, et al. Changes in bone histomorphometry after long-term treatment with intermittent cyclic etidronate for postmenopausal osteoporosis. J Bone Miner Res 1993; 8: 199-208
25. Harris ST, Watts NB, Jackson RD, et al. Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy. Am J Med 1993; 95: 557-67
26. Axelrod DW, Teitelbaum SL. Results of long term cyclical etidronate therapy: bone histomorphometry and clincial corelates [abstract no. 63]. J Bone Miner Res 1994; 9 Suppl. 1
27. Wimalawansa SJ. Combined therapy with estrogen and etidronate has an additive effect on BMD in the hip and vertebrae: four year randomized trial. Am J Med 1995; 99: 36-42
28. Dewis P, Prasad BK, Anderson DC, et al. Clinical experience with the use of two diphosphonates in the treatment of Paget's disease. Ann Rheum Dis 1985; 44: 34-8
29. Altman RD. Long term follow up of therapy with intermittent etidronate disodium in Paget's disease of bone. Am J Med 1985; 79: 583-90
30. Charbon S, Chapuy MC, Valentin-Opran A, et al. Intravenous etidronate for spinal cord dysfunction due to Paget's disease. Lancet 1982; 1: 391-2
31. Perry HM, Droke DM, Avioli LV. Alternate calcitonin and etidronate disodium therapy for Paget's bone disease. Arch Int Med 1984; 144: 929-33
32. Dewis P, Prasad BK, Anderson DC, et al. Clinical experience with the use of two diphosphonates in the treatment of Paget's disease. Ann Rheum Dis 1985; 44: 34-8
33. Chakravarty K, Merry P, Scott DGI. A single infusion of bisphosphonate AHPrBP in the treatment of Paget's disease of bone. J Rheumatol 1994; 21: 2118-21
34. Mautalen CA, Gonzalez D, Ghiringhelli CJ. Efficacy of the bisphosphonate APD in the control of Paget's disease. Bone 1985; 6: 429-32
35. Cormier C, Hilliquin P, Menkes CJ. Effects of intravenous APD in patients with refractory Paget's disease. Br J Rheum 1993; 32: 767-8
36. Bombasei GJ, Yocono M, Raisz LG. Effects of intravenous pamidronate therapy on Paget's disease of bone. Am J Med Sci 1994; 308: 226-33
37. Ryan PJ, Sherry M, Gibson T, et al. Treatment of Paget's disease by weekly infusions of APD. Br J Rheumatol 1992; 31: 97-101
38. Schweitzer DH, Zwinderman AH, Vermeij P, et al. Improved treatment of Paget's disease with APD. J Bone Miner Res 1993; 8: 175-82
39. Pepersack T, Karmali R, Gillet C, et al. Paget's disease of bone: five regimens of pamidronate treatment. Clin Rheumatol 1994; 13: 39-44
40. Reginster JY, Treves R, Renier JC, et al. Efficacy and tolerability of a new formulation of oral tiludronate in the treatment of Paget's disease of bone. J Bone Miner Res 1994; 9: 615-9
41. Adami S, Mian M, Gatti P, et al. Effects of two oral doses of alendronate in the treatment of Paget's disease of bone. Bone 1994; 15: 415-7
42. Manolagas SC, Knutson S, Jilka RL. The SAM-P/6: a model of senile osteoporosis exhibits decreased osteoclastogenesis and fails to upregulate this process following ovariectomy [abstract no. 99]. J Bone Miner Res 1993; 8 Suppl. 1
43. Fleisch H, Russell RGG, Biasz S, et al. The influence of pyrophosphate analogues (diphosphonates) on the precipitation and dissolution of calcium phosphate in vitro and in vivo. Calcif Tissue Res 1968; 2 Suppl.: 10
44. Stone M, Didronel PMO. Br J Hosp Med 1993; 49: 275
45. Walls NB. Treatment of osteoporosis with bisphosphonates. Rheum Dis Clin North Am 1994; 20: 717-34
46. Fleisch H. The use of bisphosphonates in osteoporosis. Br J Clin Pharm 1994; 48: 323-6
47. Storm T, Thamsborg G, Steiniche T, et al. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med 1990; 322: 1265-71
48. Watts NB, Harris ST, Genant HK, et al. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 1990; 323: 73-9
49. Frost HM. Treatment of osteoporosis by manipulation of coherent bone cell population. Clin Orthop Rel Res 1979; 143: 227-44
50. Pacifici R, McMurtry C, Vered I, et al. Coherence therapy does not present axial bone loss in osteoporotic women: a preliminary comparative study. J Clin Endocrinol Metab 1988; 66: 747-52
51. Hodsman AB. Effects of cyclical therapy for osteoporosis using an oral regimen of inorganic phosphate and sodium etidronate: a clinical and bone histormorphometric study. Bone Miner 1989; 5: 201
52. Marcus R. Cyclic etidronate: has the rose lost its bloom? Am J Med 1993; 95: 555-6
53. Anderson DC. Alendronate: some remaining paradoxes. Osteoporos Int 1993; 3 Suppl. 3: S41-2
54. Rodan GA, Seedor JG, Balena R. Preclinical pharmacology of alendronate. Osteoporos Int 1993; 3 Suppl. 3: S7-12
55. Gertz BJ, Holland SD, Kline WF, et al. Clinical pharmacology of alendronate sodium. Osteoporos Int 1993; 3 Suppl. 3: S13-16
56. Chesnut CH, Harris ST. Short-term effect of alendronate on bone mass and bone remodeling in postmenopausal women. Osteoporos Int 1993; 3 Suppl. 3: S17-19
57. Rossini M, Gatti D, Zamberlan N. Long-term effects of a treatment course with oral alendronate of postmenopausal osteoporosis. J Bone Miner Res 1994; 9: 1833-7
58. Chestnut C, McClung MR, Ensred KE, et al. Alendronate treatment of the postmenopausal osteoporotic women: effects of multiple dosages on bone mass and bone remodeling. Am J Med 1995; 99: 144-52
59. Lieberman UA, Weiss SR, Broll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995; 33: 1437-43
60. Black DM, Reiss TF, Nevitt MC, et al. Design of the fracture intervention trial. Osteoporos Int 1993; 3 Suppl. 3: S29-39
61. Mulder H, Struys A. Intermittent cyclical etidronate in the prevention of corticosteroid-induced bone loss. Br J Rheumatol 1994; 33: 348-50
62. Adachi JD, Bensen WG, Dorizzi R, et al. Intermittent cyclic etidronate therapy (ICT) prevents corticosteroid-induced bone loss [abstract no. 35]. J Bone Miner Res 1993; 8 Suppl. 1
63. Miller PD, Hamilos DL, McIntyre DO, et al. Cyclical etidronate (CE) increases bone mass in patients with established steroid-induced osteoporosis (SIOP) [abstract no. 889]. J Bone Miner Res 1993; 8 Suppl. 1
64. Lukert BP. Etidronate in the management of glucocorticoid-induced osteoporosis. Am J Med 1995; 99: 232-4
65. Lane NE, Genant HK, Kinney JH. Effect of intermittent cyclic etidronate therapy for glucocorticoid induced osteoporosis in rheumatoid arthritis: interim analysis [abstract no. 262]. J Bone Miner Res 1993; 8 Suppl. 1
66. Adachi J, Cranney A, Goldsmith CH, et al. Intermittent cyclic etidronate therapy in the prevention of corticosteroid induced bone loss. J Rheumatol 1994 Oct; 21: 1922-6
67. Struys A, Sneler AA, Mulder H. Cyclic etidronate reverses bone loss of the spine and proximal femur in patients with established corticosteroid induced osteoporosis. Am J Med 1995; 99: 235-40
68. Reid IR, King AR, Alexander CJ, et al. Prevention of steroid-induced osteoporosis with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD). Lancet 1988; 1: 143
69. Reid IR, Schooler BA, Stewart AW. Prevention of glucocorticoid-induced osteoporosis. J Bone Miner Res 1990; 5: 619
70. Gallacher SJ, Anderson K, Fenner JA, et al. Intravenous pamidronate in the treatment of osteoporosis associated with corticosteroid dependent lung disease: an open pilot study. Thorax 1992; 47: 932
71. Lufkin EG, Argueta R, Whitaker MD, et al. Pamidronate: an unrecognized problem in gastrointestinal tolerability. Osteoporos Int 1994; 4: 320-2
72. Lombardi A, Santora AC. Clinical trials with bisphosphonates. Bone Miner 1993; 22 Suppl. 1: S59
73. Hannuniemi R, Lauren L, Puolijoki H. Clodronate: an effective agent for the treatment of increased bone resorption. Drugs Today 1991; 27: 375
74. Passeri M, Baroni MC, Pedrazzoni M, et al. Intermittent treatment with intravenous 4-amino-1-hydroxybutylidene-1,1-bisphosphonate (AHBuBP) in the therapy of postmenopausal osteoporosis. Bone Miner 1991; 15: 237
75. Boyce BF, Smith L, Fogelman I, et al. Focal osteomalacia due to low-dose disphosphonate therapy in Paget's disease. Lancet 1984; 1: 821
76. Nagant de Deuxchaisnes C, Rombouts-Lindermans C, Haux JP, et al. Diphosphonates and inhibition of bone mineralization. Lancet 1982; 2: 607
77. Bounameauz HM. Renal failure associated with intravenous disphosphonates. Lancet 1983; 1: 471
78. Kellihan MJ, Mangino PD. Pamidronate. Ann Pharmacother 1992; 26: 1262
79. Roux C, Listrat V, Villette B, et al. Long-lasting dermatological lesions after tiludronate therapy. Calcif Tissue Int 1992; 50: 378
80. Gallacher SJ, Ralston SH, Patel U, et al. Side-effects of pamidronate. Lancet 1989; 2: 42